Mediqas Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 14-12-2024
- Paid Up Capital ₹ 1.00 M
as on 14-12-2024
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.00 M
as on 14-12-2024
- Revenue %
(FY 2021)
- Profit 504.56%
(FY 2021)
- Ebitda 1516.31%
(FY 2021)
- Net Worth 126.71%
(FY 2021)
- Total Assets 203.80%
(FY 2021)
About Mediqas Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹8.00 M.
Chandra Jha and Rinki Jha serve as directors at the Company.
- CIN/LLPIN
U24304UP2020PTC126941
- Company No.
126941
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Feb 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Mediqas Pharma Private Limited offer?
Mediqas Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Eye Drops.
Who are the key members and board of directors at Mediqas Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandra Jha  | Managing Director | 13-Apr-2020 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rinki Jha | Director | 12-Feb-2020 | Current |
Financial Performance of Mediqas Pharma.
Mediqas Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 504.56% increase in profit. The company's net worth Soared by an impressive increase of 126.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mediqas Pharma?
In 2021, Mediqas Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Feb 2021 | ₹8.00 M | Open |
How Many Employees Work at Mediqas Pharma?
Mediqas Pharma has a workforce of 40 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediqas Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediqas Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
